A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
NCT00649844, Phase 3, Completed, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs | ClinicalTrials.gov |
| NCT number | NCT00649844 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 3 | ClinicalTrials.gov |
| Enrollment | 147 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | ClinicalTrials.gov |
| Conditions | Schizophrenia | ClinicalTrials.gov |
| Interventions | Clozapine, Ziprasidone | ClinicalTrials.gov |
| First posted | 2008-04-01 | ClinicalTrials.gov |
| Last updated | 2021-02-21 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from baseline to endpoint in Positive and Negative Syndrome Scale (PANSS) total scores | Until Final Visit (within 18 weeks) | ClinicalTrials.gov | |
| Secondary | Proportion of responders, based on change from baseline to endpoint in PANSS total score | Until Final Visit (within 18 weeks) | ClinicalTrials.gov | |
| Secondary | Change from baseline to endpoint in Clinical Global Impressions-Severity (CGI-S) scores | Baseline and weekly from Weeks 1-18 | ClinicalTrials.gov | |
| Secondary | Time to discontinuation | Up to 18 weeks | ClinicalTrials.gov | |
| Secondary | Change from baseline to endpoint in cognitive function assessments, including Rey serial verbal learning test, Stroop Color Word test, and Trail Making Test | Baseline and Weeks 12 and 18 | ClinicalTrials.gov | |
| Secondary | Change from baseline to endpoint in Global Assessment of Functioning (GAF) scores | Baseline and Week 8, 12, and 18 | ClinicalTrials.gov | |
| Secondary | Change from baseline in Modified Resource Utilization Questionnaire (RUQ) scores | Baseline and Weeks 4, 8, 12, and 18 | ClinicalTrials.gov | |
| Secondary | Change from baseline to endpoint in Drug Attitude Inventory (DAI) scores | Screening and Weeks 1, 8, 12, and 18 | ClinicalTrials.gov | |
| Secondary | Change from baseline to endpoint in PANSS subscale scores | Baseline and weekly from Weeks 1-18 | ClinicalTrials.gov | |
| Secondary | Adverse events | Weekly from Weeks 1-18 | ClinicalTrials.gov | |
| Secondary | Change from baseline to endpoint in Calgary Depression Scale (CDSS) scores | Baseline and Weeks 8, 12, and 18 | ClinicalTrials.gov | |
| Secondary | Change from baseline in Caregiver Activity Survey (CAS) | Screening and Weeks 1, 8, 12, and 18 | ClinicalTrials.gov | |
| Secondary | Change from baseline in laboratory tests | Screening and weekly from Weeks 1-18 | ClinicalTrials.gov | |
| Secondary | Change from baseline in electrocardiogram | Screening and Weeks 1, 8, 12, and 18 | ClinicalTrials.gov | |
| Secondary | Change from baseline in movement disorder rating scales, including Barnes Akathisia Rating Scale, Abnormal Involuntary Movement Scale, and Simpson-Angus Scale | Baseline and Weeks 1, 8, 12, and 18 | ClinicalTrials.gov | |
| Secondary | Change from baseline to endpoint in Clinical Global Impressions-Improvement (CGI-I) scores | Baseline and weekly from Weeks 1-18 | ClinicalTrials.gov | |
| Secondary | Change from baseline to endpoint in Patient Preference Scale (PPS) scores | Screening and Weeks 1, 8, 12, and 18 | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)